Facility already supplying Granules' JV partner Ajinomoto Omnichem with validation batches

Granules predicts US and EMA approval for new API plant in two years

By Gareth Macdonald

- Last updated on GMT

Granules India and Ajinomoto Omnichem's new API plant inaugurated
Granules India and Ajinomoto Omnichem's new API plant inaugurated
An API and intermediates plant set up by Granules India and Ajinomoto Omnichem is a step closer to opening after an offical inauguration ceremony last week. 

India’s Granules and Belgian fine chemicals firm Ajinomoto Omnichem partnered to set up the facility in Visakhapatnam, Andhra Pradesh in 2011​, touting the site as a production hub for low volume, high value active pharmaceutical ingredients (APIs) and intermediates.

The plant was inaugurated on Friday by Mr. M. Venkaiah Naidu, Hon’ble Union Minister for Urban Development, Housing and Urban Poverty Alleviation and Parliamentary Affairs and other members of the Indian Government.


The facility cost $20m (€14m) to build and was due to be operational in 2013, but according to Granules India managing director Krishna Prasad Chigurupati the opening was put back in response to design changes requested by customers.

We had initially planned to open the facility by 2013. However, we incorporated some design changes in the facility as recommended by our customers and therefore, consciously pushed the inaugural date to 2015​.”

Chigurupati told in-Pharmatechnologist.com that initially the plant “will supply its products to Ajinomoto OmniChem to cater to the requirements of the Ajinomoto OmniChem customers​.”

EU and US customers

Once the facility has received the required regulatory approvals the plan is to supply other customers in European and the US directly according to Chigurupati, who added that the plant “will not supply any of its finished products to India.”

He predicted these approvals will take two years to obtain, after which customer supply will begin.

He added that: “The sale of validation batches has already started, and we will continue to supply the intermediaries until we receive the US Food and Drug Administration and European approval for the site​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more